Table 3.

Clinical studies registered in Clinicaltrials.gov for hematologic and oncologic patients in the US and in Europe.

NCT#	Study	Primary Outcome Measurements	Number of Patients (n)
02928523	PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients (ODYSSEE)	Evaluation of efficacy in dysbiosis correction and multidrug resistant bacteria based on bacterial culture	20
03678493	A Study of FMT in Patients With AML Allo HSCT in Recipients	Efficacy of FMT in AML patients and allo-HSCT recipients in reducing the incidence of infections	120
04935684	Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation (TMF-Allo)	GVHD and relapse-free survival rate after allogeneic hematopoietic stem cell transplantation	150
04269850	Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD (JAK-FMT)	Overall survival	20
05094765	Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of GI-aGVHD	Overall survival and Grade 3 or above adverse events	15
02269150	Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation	CDI up to one year after entry into study	59
03214289	Fecal Microbiota Transplantation for Steroid Resistant and Steroid Dependent Gut Acute Graft Versus Host Disease	Serious adverse events	4
02733744	Fecal Microbiota Transplantation After HSCT	Feasibility on the number of participants able to ingest 15 FMT capsules over a 2-day period	18
03359980	Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer (HERACLES)	Efficacy of FMT in steroid refractory -gastro-intestinal acute GVHD at Day 28	24
03819803	Fecal Microbiota Transplantation in aGvHD After ASCT	Remission at Day 90	15
04038619	Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients	Tolerability and response	40
02770326	Safety of Stool Transplant for Patients With Difficult to Treat C. Difficile Infection	Incidence of CDI	10
04116775	Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.	Anticancer effect of FMT from responders to pembrolizumab to non-responders.	32
04040712	Fecal Microbiota Transplantation in Diarrhea Induced by Tyrosine-kinase Inhibitors	Resolution of diarrhea four weeks after FMT	20
03819296	Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer	Differences in stool microbiome pattern and adverse events	800
04951583	Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma (FMT-LUMINATE)	Overall response rate	70
04521075	A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC	Overall response rate and adverse events	42
04163289	Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation (PERFORM)	Rate of immune-related colitis associated with ipilimumab/nivolumab treatment	20
04729322	Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders	Overall response rate	15
04924374	Microbiota Transplant in Advanced Lung Cancer Treated With Immunotherapy	Measurements of safety	20
03341143	Fecal Microbiota Transplant (FMT) in Melanoma Patients	Overall response rate	18
03353402	Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy	Rate of adverse events and engraftment	40
04988841	Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma (PICASSO)	Safety and tolerability	60
04577729	The IRMI-FMT Trial	Progression-free survival	60